MBX Biosciences, Inc. (MBX)
| Market Cap | 1.48B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.50M |
| Shares Out | 44.90M |
| EPS (ttm) | -2.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 645,102 |
| Open | 34.07 |
| Previous Close | 34.49 |
| Day's Range | 32.85 - 34.58 |
| 52-Week Range | 4.81 - 34.83 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 56.17 (+70.21%) |
| Earnings Date | Nov 6, 2025 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price target is $56.17, which is an increase of 70.21% from the latest price.
News
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no sh...
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross p...
MBX Biosciences to Participate in November Investor Conferences
CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.
MBX Biosciences, Inc. - Special Call
MBX Biosciences, Inc. - Special Call Company Participants Jim DeNike Peter Hawryluk - CEO, President & Director Salomon Azoulay - Chief Medical Officer Conference Call Participants Seamus Fernandez - ...
MBX Biosciences Announces Pricing of Upsized Public Offering
CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market
MBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and co...
MBX Biosciences Announces Proposed Public Offering
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 Preclinical data support the potential for improved weight loss and tolera...
Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q3 2025 Earnings Conference Call August 14, 2025 10:00 AM ET Company Participants Cameron L. Groome - President, CEO & Director James S.
Mbx Biosciences (MBX) Q2 Loss Widens 22%
Mbx Biosciences (MBX) Q2 Loss Widens 22%
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia an...
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX's novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 202...
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy
MBX Biosciences offers a unique prodrug approach with three promising candidates targeting hypoparathyroidism, post-bariatric hypoglycemia, and obesity - two of its three drug candidates are GLP recep...
MBX Biosciences to Participate in June Investor Conferences
CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide thera...
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 mil...
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...